Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 34

1.

Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis.

Cheng J, Zhang W, Zhang X, Li X, Chen J.

Clin J Am Soc Nephrol. 2012 Mar;7(3):391-400. doi: 10.2215/CJN.03000311. Epub 2012 Jan 5. Review. Erratum in: Clin J Am Soc Nephrol. 2012 Jun;7(6):1053.

2.

Oral calcitriol for reduction of proteinuria in patients with IgA nephropathy: a randomized controlled trial.

Liu LJ, Lv JC, Shi SF, Chen YQ, Zhang H, Wang HY.

Am J Kidney Dis. 2012 Jan;59(1):67-74. doi: 10.1053/j.ajkd.2011.09.014. Epub 2011 Oct 22.

PMID:
22019331
3.

Oral cholecalciferol decreases albuminuria and urinary TGF-β1 in patients with type 2 diabetic nephropathy on established renin-angiotensin-aldosterone system inhibition.

Kim MJ, Frankel AH, Donaldson M, Darch SJ, Pusey CD, Hill PD, Mayr M, Tam FW.

Kidney Int. 2011 Oct;80(8):851-60. doi: 10.1038/ki.2011.224. Epub 2011 Aug 10.

4.

Prognosis of CKD patients receiving outpatient nephrology care in Italy.

De Nicola L, Chiodini P, Zoccali C, Borrelli S, Cianciaruso B, Di Iorio B, Santoro D, Giancaspro V, Abaterusso C, Gallo C, Conte G, Minutolo R; SIN-TABLE CKD Study Group.

Clin J Am Soc Nephrol. 2011 Oct;6(10):2421-8. doi: 10.2215/CJN.01180211. Epub 2011 Aug 4.

5.

Antiproteinuric response to add-on aliskiren in proteinuric patients treated with dual blockade of the renin-angiotensin system: a 12-month prospective uncontrolled study.

De Nicola L, Zamboli P, Bellizzi V, Stanzione G, Russo D, Nappi F, Minco M, Chiodini P, Conte G, Minutolo R.

Am J Kidney Dis. 2011 Jun;57(6):961-3. doi: 10.1053/j.ajkd.2011.02.384. Epub 2011 Apr 19. No abstract available.

PMID:
21507536
6.

Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial.

de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, Parving HH, Pritchett Y, Remuzzi G, Ritz E, Andress D.

Lancet. 2010 Nov 6;376(9752):1543-51. doi: 10.1016/S0140-6736(10)61032-X.

PMID:
21055801
7.

Are vitamin D receptor agonists like angiotensin-converting enzyme inhibitors without side effects?

Agarwal R.

Kidney Int. 2010 Jun;77(11):943-5. doi: 10.1038/ki.2010.77.

8.

Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes.

Deb DK, Sun T, Wong KE, Zhang Z, Ning G, Zhang Y, Kong J, Shi H, Chang A, Li YC.

Kidney Int. 2010 Jun;77(11):1000-9. doi: 10.1038/ki.2010.22. Epub 2010 Feb 24.

9.

Intensive versus conventional therapy to slow the progression of idiopathic glomerular diseases.

Bianchi S, Bigazzi R, Campese VM.

Am J Kidney Dis. 2010 Apr;55(4):671-81. doi: 10.1053/j.ajkd.2009.11.006. Epub 2010 Jan 25.

PMID:
20097461
10.

Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial.

Fishbane S, Chittineni H, Packman M, Dutka P, Ali N, Durie N.

Am J Kidney Dis. 2009 Oct;54(4):647-52. doi: 10.1053/j.ajkd.2009.04.036. Epub 2009 Jul 12.

PMID:
19596163
11.

Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration.

Levey AS, Cattran D, Friedman A, Miller WG, Sedor J, Tuttle K, Kasiske B, Hostetter T.

Am J Kidney Dis. 2009 Aug;54(2):205-26. doi: 10.1053/j.ajkd.2009.04.029. Epub 2009 Jul 3.

PMID:
19577347
12.

Renoprotective effects of vitamin D analogs.

Li YC.

Kidney Int. 2010 Jul;78(2):134-9. doi: 10.1038/ki.2009.175. Epub 2009 May 27.

13.

The importance of the intrarenal renin-angiotensin system.

Velez JC.

Nat Clin Pract Nephrol. 2009 Feb;5(2):89-100. doi: 10.1038/ncpneph1015. Epub 2008 Dec 9. Review.

PMID:
19065132
14.

Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase.

Zhang Z, Zhang Y, Ning G, Deb DK, Kong J, Li YC.

Proc Natl Acad Sci U S A. 2008 Oct 14;105(41):15896-901. doi: 10.1073/pnas.0803751105. Epub 2008 Oct 6.

15.

Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial.

Alborzi P, Patel NA, Peterson C, Bills JE, Bekele DM, Bunaye Z, Light RP, Agarwal R.

Hypertension. 2008 Aug;52(2):249-55. doi: 10.1161/HYPERTENSIONAHA.108.113159. Epub 2008 Jul 7.

16.

Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of NF-kappaB signaling.

Tan X, Wen X, Liu Y.

J Am Soc Nephrol. 2008 Sep;19(9):1741-52. doi: 10.1681/ASN.2007060666. Epub 2008 Jun 4.

17.

Role of remission clinics in the longitudinal treatment of CKD.

Ruggenenti P, Perticucci E, Cravedi P, Gambara V, Costantini M, Sharma SK, Perna A, Remuzzi G.

J Am Soc Nephrol. 2008 Jun;19(6):1213-24. doi: 10.1681/ASN.2007090970. Epub 2008 Mar 19.

18.

Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease.

Kunz R, Friedrich C, Wolbers M, Mann JF.

Ann Intern Med. 2008 Jan 1;148(1):30-48. Epub 2007 Nov 5.

PMID:
17984482
19.

Direct renin inhibition with aliskiren in hypertension and target organ damage.

Müller DN, Luft FC.

Clin J Am Soc Nephrol. 2006 Mar;1(2):221-8. Epub 2005 Dec 22. Review.

20.

Diagnostic thresholds for ambulatory blood pressure monitoring based on 10-year cardiovascular risk.

Kikuya M, Hansen TW, Thijs L, Björklund-Bodegård K, Kuznetsova T, Ohkubo T, Richart T, Torp-Pedersen C, Lind L, Ibsen H, Imai Y, Staessen JA; International Database on Ambulatory blood pressure monitoring in relation to Cardiovascular Outcomes Investigators.

Circulation. 2007 Apr 24;115(16):2145-52. Epub 2007 Apr 9.

Items per page

Supplemental Content

Write to the Help Desk